As of 2025-04-18, the EV/EBITDA ratio of Avidity Biosciences Inc (RNA) is -7.64. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Avidity's latest enterprise value is 2,876.74 mil USD. Avidity's TTM EBITDA according to its financial statements is -376.41 mil USD. Dividing these 2 quantities gives us the above Avidity EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.7x - 11.3x | 9.5x |
| Forward P/E multiples | 20.0x - 21.5x | 20.1x |
| Fair Price | (60.92) - (33.55) | (44.51) |
| Upside | -336.5% - -230.3% | -272.8% |
| Date | EV/EBITDA |
| 2025-04-04 | -7.90 |
| 2025-04-03 | -8.39 |
| 2025-04-02 | -8.92 |
| 2025-04-01 | -7.96 |
| 2025-03-31 | -8.84 |
| 2025-03-28 | -9.51 |
| 2025-03-27 | -9.81 |
| 2025-03-26 | -9.65 |
| 2025-03-25 | -9.67 |
| 2025-03-24 | -10.05 |
| 2025-03-21 | -9.26 |
| 2025-03-20 | -9.26 |
| 2025-03-19 | -9.55 |
| 2025-03-18 | -9.15 |
| 2025-03-17 | -10.22 |
| 2025-03-14 | -9.35 |
| 2025-03-13 | -9.68 |
| 2025-03-12 | -9.83 |
| 2025-03-11 | -8.86 |
| 2025-03-10 | -9.01 |
| 2025-03-07 | -9.09 |
| 2025-03-06 | -9.11 |
| 2025-03-05 | -8.85 |
| 2025-03-04 | -8.54 |
| 2025-03-03 | -8.75 |
| 2025-02-28 | -9.20 |
| 2025-02-27 | -8.70 |
| 2025-02-26 | -8.88 |
| 2025-02-25 | -8.73 |
| 2025-02-24 | -9.17 |
| 2025-02-21 | -9.35 |
| 2025-02-20 | -9.80 |
| 2025-02-19 | -9.60 |
| 2025-02-18 | -9.64 |
| 2025-02-14 | -9.73 |
| 2025-02-13 | -9.96 |
| 2025-02-12 | -9.58 |
| 2025-02-11 | -10.21 |
| 2025-02-10 | -10.37 |
| 2025-02-07 | -10.57 |
| 2025-02-06 | -10.63 |
| 2025-02-05 | -10.49 |
| 2025-02-04 | -10.06 |
| 2025-02-03 | -9.62 |
| 2025-01-31 | -9.93 |
| 2025-01-30 | -9.84 |
| 2025-01-29 | -9.61 |
| 2025-01-28 | -9.66 |
| 2025-01-27 | -9.14 |
| 2025-01-24 | -8.89 |